Published in Oncotarget on July 30, 2014
Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor. Dis Markers (2015) 0.80
Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. Oncotarget (2016) 0.75
Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients. Oncotarget (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
The retinoblastoma protein and cell cycle control. Cell (1995) 20.21
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet (2007) 9.88
Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature (1996) 4.05
Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol (2005) 2.45
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer (2003) 2.18
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05
Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res (2001) 1.95
Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One (2010) 1.93
Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res (2001) 1.84
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80
Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res (1999) 1.74
Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74
Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. Proc Natl Acad Sci U S A (2000) 1.72
Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol (2002) 1.68
TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res (2013) 1.39
Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res (2002) 1.36
Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res (2007) 1.32
Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.30
Molecular biomarkers in urothelial bladder cancer. Cancer Sci (2008) 1.29
Gender differences in stage distribution of bladder cancer. Urology (2000) 1.25
Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer (2005) 1.25
Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res (2003) 1.22
Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst (2008) 1.18
Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Mol Cancer (2007) 1.17
Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol (2000) 1.16
CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer (2004) 1.14
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer (2010) 1.13
The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res (2002) 1.10
Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene. J Virol (1995) 1.09
Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Res (2002) 1.07
Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol (2007) 1.06
Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol (1999) 1.02
Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res (2003) 1.00
Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int J Cancer (2003) 0.98
Molecular pathways in bladder cancer. Urol Res (2004) 0.95
p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res (2002) 0.95
Cancer epigenetics: above and beyond. Toxicol Mech Methods (2011) 0.95
PUMA in head and neck cancer. Cancer Lett (2003) 0.94
Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. Int J Cancer (2003) 0.93
Epigenomics and ovarian carcinoma. Biomark Med (2010) 0.91
Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer. Br J Cancer (2003) 0.91
Multivalent pseudopeptides targeting cell surface nucleoproteins inhibit cancer cell invasion through tissue inhibitor of metalloproteinases 3 (TIMP-3) release. J Biol Chem (2012) 0.87
Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. Carcinogenesis (2014) 0.87
Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine. Oncotarget (2014) 0.83
Absence of the basement membrane component nidogen 2, but not of nidogen 1, results in increased lung metastasis in mice. J Histochem Cytochem (2012) 0.80